What factors contribute to the development of therapy-related AML or MDS?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak to Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked: what factors contribute to the development of therapy-related acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)?

In this video, Eunice Wang describes how genomic sequencing techniques and technologies have allowed us to dissect the clonal evolution and background that underlies these hematological malignancies. She also discusses factors such as ageing and prior exposure to chemotherapy or radiation.